Trimetazidine has an antianginal, antihypoxic effect.
Directly affecting the cardiomyocytes and neurons of the brain, it optimizes their metabolism and function. The cytoprotective effect is due to an increase in the energy potential, activation of oxidative decarboxylation, and rationalization of oxygen consumption (enhancement of aerobic glycolysis and fat oxidation blockade). Supports contractility of the myocardium, prevents intracellular depletion of ATP and phosphocreatinine. Under conditions of acidosis, normalizes the functioning of ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular content of the calium ions. Reduces intracellular acidosis and phosphate content due to myocardial ischemia and reperfusion.
Prevents the damaging effect of free radicals, preserves the integrity of cell membranes,prevents the activation of neutrophils in the ischemia zone, prolongs the duration of the electrical potential, reduces the yield of creatine phosphokinase from cells and the severity of myocardial ischemic damage.
When angina reduces the frequency of attacks (reduces the consumption of nitrates), after 2 weeks of treatment increases exercise tolerance, blood pressure drops decrease without any significant changes in heart rhythms. Improves hearing and results of vestibular samples in patients with pathology of ENT organs, reduces dizziness and tinnitus. In vascular pathology, the eye restores the functional activity of the retina.